The major players in the unresectable hepatocellular carcinoma market include Eisai Co., Ltd, Bayer AG, Bristol- Myers Squibb Company, Sumitomo Dainippon Pharma Co., Ltd, Glaxosmithkline Plc. The entire unresectable hepatocellular carcinoma market has been sub-categorized into treatment and end-user.
current and future demand for unresectable hepatocellular carcinoma market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Hepatocellular carcinoma is one of the most prevalent worldwide. It is associated with a very low 5-year survival rate. Very few patients with HCC qualify for surgical resection or liver transplantation, as more than half of all HCCs are diagnosed at an advanced stage of the disease. Asia contributes a particularly large prevalence of the global hepatocellular carcinoma (HCC), accounting for nearly two-thirds of the newly diagnosed. The majority of HCC patients are diagnosed at unresectable stages. Intraarterial therapy (IAT), specifically transarterial chemoembolization, is considered the standard of care in patients with unresectable HCC. Other recent options are sorafenib, regorafenib, nivolumab, lenvatinib, pembrolizumab, cabozantinib, and ramucirumab. However, there is no evidence that currently used anatomic response criteria are adequate for overall survival because tumour shrinkage is rarely observed in patients with unresectable HCC after IAT.
By Treatment
- Chemotherapy
- Molecularly Targeted Therapy
- Immunotherapy
By End-Use
- Hospitals
- Specialty Clinics
- Cancer Centers
- Research institutes
Source: https://www.valuemarketresearch.com/report/unresectable-hepatocellular-carcinoma-market
Naira Shekhawat has been into Content Writing just after completing her Graduation in English Literature. Her love for words has won her many accolades in her respective jobs ever since. Naira covers business sections for VMR News. She is a traveller by heart and loves writing on food blogs as a freelancer.